Your session is about to expire
← Back to Search
Radiation
Adaptive Radiotherapy for Brain Tumor
N/A
Recruiting
Led By Tony J. Wang, MD
Research Sponsored by Columbia University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Plan to receive 60 Gy in 30 fractions of radiotherapy and not hypofractionated radiotherapy and not hypofractionated radiotherapy including 40 Gy in 15 fractions
Histopathologically proven diagnosis of glioblastoma, anaplastic astrocytoma, or anaplastic oligodendroglioma
Must not have
Prior malignancy (except non-melanomatous skin cancer) unless disease free for a minimum of 2 years
Prior therapy for tumor except for biopsy or resection, including prior radiotherapy to the brain
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 years
Awards & highlights
No Placebo-Only Group
Summary
This trial investigates if MRI scans during radiation can improve treatment of high-grade brain tumors.
Who is the study for?
This trial is for adults over 18 with high-grade gliomas like glioblastoma, who haven't had previous tumor treatments except biopsy or resection. They must have a Karnofsky performance status of 70+ and plan to receive standard radiotherapy. Pregnant women can't participate.
What is being tested?
The study tests if extra MRI scans during the weekly radiation treatment can improve outcomes for patients with aggressive brain tumors. It aims to adapt radiotherapy more precisely to the changes in the tumor's size and shape.
What are the potential side effects?
While not explicitly listed, side effects may include typical reactions from regular MRIs and radiotherapy such as headaches, nausea, fatigue, skin irritation at the treatment site, and potential short-term memory issues.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
I am scheduled for a specific radiotherapy plan, not a shortened course.
Select...
My diagnosis is a type of aggressive brain tumor.
Select...
I am able to care for myself but cannot do normal activities without help.
Select...
I am 18 years old or older.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have been cancer-free for at least 2 years, except for non-melanoma skin cancer.
Select...
I have only had a biopsy or surgery for my tumor, no other treatments.
Select...
My cancer has spread outside the brain.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 years
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 years
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Prediction of progression of disease in patients with high-grade glioma.
Secondary study objectives
Estimate the progression-free and overall survival in patient with high-grade glioma.
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Adaptive RadiotherapyExperimental Treatment1 Intervention
Subjects will receive radiotherapy per standard of care over 30-33 once-daily fractions in addition to 7 brain MRIs each in every week of treatment. Subjects receiving hypofractionated radiotherapy will receive radiotherapy per standard of care over 15 once-daily fractions in addition to 4 brain MRIs each in every week of treatment.
Find a Location
Who is running the clinical trial?
Columbia UniversityLead Sponsor
1,486 Previous Clinical Trials
2,655,296 Total Patients Enrolled
1 Trials studying Oligodendroglioma
15 Patients Enrolled for Oligodendroglioma
Varian Medical SystemsIndustry Sponsor
61 Previous Clinical Trials
3,613 Total Patients Enrolled
Tony J. Wang, MDPrincipal InvestigatorColumbia University
Share this study with friends
Copy Link
Messenger